Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

580 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists.
Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, Hamlington J, Barnard MR, Kickler T, Christie DJ, Kundu S, Bray PF. Michelson AD, et al. Among authors: hendrix c. Circulation. 2000 Mar 7;101(9):1013-8. doi: 10.1161/01.cir.101.9.1013. Circulation. 2000. PMID: 10704169
Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects.
Stone ND, Dunaway SB, Flexner C, Tierney C, Calandra GB, Becker S, Cao YJ, Wiggins IP, Conley J, MacFarland RT, Park JG, Lalama C, Snyder S, Kallungal B, Klingman KL, Hendrix CW. Stone ND, et al. Among authors: hendrix cw. Antimicrob Agents Chemother. 2007 Jul;51(7):2351-8. doi: 10.1128/AAC.00013-07. Epub 2007 Apr 23. Antimicrob Agents Chemother. 2007. PMID: 17452489 Free PMC article. Clinical Trial.
Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection.
Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, Brown S, Jackson JB, Coombs RW, Glesby MJ, Flexner CW, Bridger GJ, Badel K, MacFarland RT, Henson GW, Calandra G; AMD3100 HIV Study Group. Hendrix CW, et al. J Acquir Immune Defic Syndr. 2004 Oct 1;37(2):1253-62. doi: 10.1097/01.qai.0000137371.80695.ef. J Acquir Immune Defic Syndr. 2004. PMID: 15385732 Clinical Trial.
High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis.
Matthews LT, Heffron R, Mugo NR, Cohen CR, Hendrix CW, Celum C, Bangsberg DR, Baeten JM; Partners PrEP Study Team. Matthews LT, et al. Among authors: hendrix cw. J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):91-7. doi: 10.1097/QAI.0000000000000246. J Acquir Immune Defic Syndr. 2014. PMID: 25118795 Free PMC article. Clinical Trial.
When is a PrEP candidate ready for phase 3?
Hendrix C. Hendrix C. Lancet HIV. 2016 Dec;3(12):e551-e553. doi: 10.1016/S2352-3018(16)30162-X. Epub 2016 Sep 16. Lancet HIV. 2016. PMID: 27658865 No abstract available.
580 results